Minisiston (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol and Levonorgestrel, the active ingredients in Minisiston, are a combined oral contraceptive presented as an oral tablet for oral use. They prevent pregnancy in women of reproductive age.

GNH USA supplies Minisiston as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Minisiston is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle to prevent pregnancy. - Pregnancy prevention: provides reliable contraception to avoid unintended pregnancy in women of childbearing age. - Contraception: offers a hormonal method for family planning and birth control. - Menstrual cycle regulation: helps to regularise menstrual bleeding patterns and reduce dysmenorrhoea.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: temporary swelling or discomfort. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Stroke: cerebrovascular accident presenting with neurological deficits. - Myocardial infarction: heart attack symptoms such as chest pain. - Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty.

Before starting Minisiston, consider the following precautions: - Contraindication: do not use if you have a history of thromboembolic disorders. - Smoking: avoid if you are over 35 and smoke regularly. - Pregnancy: discontinue immediately if pregnancy is confirmed. - Liver disease: use with caution in patients with active liver disease. - Breastfeeding: consult a healthcare professional before use while nursing. - Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Minisiston may interact with other medicines as follows: Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness. - Rifampicin: decreases plasma levels of both hormones. - St. John’s Wort: herbal inducer that can lower efficacy. - Griseofulvin: antifungal that may diminish hormonal levels.

Moderate Interactions (Monitor Closely): - Antifungals such as ketoconazole: may increase hormone concentrations. - HIV protease inhibitors (e.g., ritonavir): can alter hormone metabolism. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of bleeding. - Diuretics: may affect fluid balance and blood pressure.